Health & Science

It’s cheap, easy to make and in demand overseas. So why can’t this Texas-born COVID-19 vaccine break into the U.S. market?

A Houston vaccine team would like a U.S. distributor but for now focuses its efforts abroad to inoculate those in countries where COVID-19 variants surface more quickly.

Maria Bottazzi, left, and Peter Hotez at the Tropical Medicine Lab at Texas Children’s Hospital Center for Vaccine Development in Houston on Oct. 5, 2021.
Maria Bottazzi replaces vials of the RBD-based SARS-CoV-2 vaccine into a freezer at the Tropical Medicine Lab at Texas Children’s Hospital Center for Vaccine Development in Houston on Oct. 5, 2021.

A Texas-style vaccine

Maria Bottazzi holds a vial of the RBD-based SARS-CoV-2 vaccine at the Tropical Medicine Lab at Texas Children’s Hospital Center for Vaccine Development in Houston on Oct. 5, 2021.

Competition from new tech

"Whatever gets the job done the fastest as long as it’s safe for everybody involved," he said.

Peter Hotez at the Tropical Medicine Lab at Texas Children’s Hospital Center for Vaccine Development in Houston on Oct. 5, 2021.

‘One plane flight away'

American problem, international solution

Subscribe to Today in Houston

Fill out the form below to subscribe our new daily editorial newsletter from the HPM Newsroom.

* required

Share